高端一期臨床試驗
After the second vaccination, the SARS-CoV-2 spike specific IgG
titers increased with peak geometric mean titers at 7178.245 (LD), 7746.086
(MD), and 11220.58 (HD), respectively.
論文出處: https://www.medrxiv.org/content/10.1101/2021.03.31.21254668v1
AZ二期臨床試驗
In participants who received two doses of vaccine, median anti-spike
SARS-CoV-2 IgG responses 28 days after the boost dose were similar across the three age cohorts
(standard-dose groups: 18–55 years, 20713 arbitrary units [AU]/mL [IQR 13898
–33550], n=39; 56–69 years, 16170 AU/mL [10233–40353], n=26; and >70 years 17561 AU/mL [9705–37796], n=47; p=0.68)
論文出處:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1
結論：
從高端一期報告來看
高端抗體效價要贏過AZ應該不容易
但兩者試驗族群不同(東方VS西方國家)
所以還是要以AZ近來台灣施打後的抗體報告為準